Lenalidomide

• Background:

  Clinically, lenalidomide has proven to be effective in the treatment of multiple myeloma and other B cell diseases. It has the ability to selectively bind and ubiquitinate two lymphoid transcription factors, IKZF1 and IKZF2, via the CRBN-CRL4 ubiquitin ligase. This ultimately leads to the degradation of IKZF1 and IKZF2, which are both essential in myeloma cell survival.

• Description:

  Ubiquitin ligase inducer

• Product Name Alternative:

  3- (7-amino-3-oxo-1H-isoindol-2-yl) piperidine-2,6-dione

• UNSPSC:

  41116105

• Type:

  Inducer

• Source:

  Synthetic

• Field of Research:

  Cell Signaling | Post-translational Modifications

• Purity:

  >98% (TLC) ; NMR (Conforms)

• Weight:

  0.01

• Format:

  Powder

• Solubility:

  Soluble in DMSO (200 mM), Water (<1 mM) and Ethanol (<1 mM).

• Molecular Formula:

  C13H13N3O3

• Molecular Weight:

  259.26

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations:

  1. Krönke J., et al. (2014) Science. 343(6168): 301-5. 2. Lu G., et al. (2014) Science. 343(6168): 305-9.

• CAS Number:

  191732-72-6